Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis
Immix Biopharma (IMMX) has announced a virtual Key Opinion Leader (KOL) event scheduled for June 3, 2025, at 3:00pm ET. The event will discuss interim clinical data from the NEXICART-2 Phase 1/2 clinical trial of their cell therapy NXC-201 in patients with relapsed/refractory AL Amyloidosis, following its presentation at the 2025 American Society of Clinical Oncology (ASCO) conference.
The event will feature prominent experts including Dr. Heather Landau from Memorial Sloan-Kettering Cancer Center, Dr. Shahzad Raza from Cleveland Clinic, and Dr. Jeffrey Zonder from Karmanos Cancer Institute. These specialists will share their clinical experience with NXC-201 and discuss the evolving treatment landscape for AL Amyloidosis. A live Q&A session will follow the presentation.
Immix Biopharma (IMMX) ha annunciato un evento virtuale con Key Opinion Leader (KOL) previsto per il 3 giugno 2025 alle 15:00 ET. Durante l'evento verranno discussi i dati clinici intermedi dello studio NEXICART-2 di fase 1/2 sulla terapia cellulare NXC-201 in pazienti con amiloidosi AL recidivante/refrattaria, a seguito della presentazione avvenuta alla conferenza 2025 dell'American Society of Clinical Oncology (ASCO).
L'evento vedrà la partecipazione di esperti di rilievo come la Dott.ssa Heather Landau del Memorial Sloan-Kettering Cancer Center, il Dott. Shahzad Raza della Cleveland Clinic e il Dott. Jeffrey Zonder del Karmanos Cancer Institute. Questi specialisti condivideranno la loro esperienza clinica con NXC-201 e discuteranno l'evoluzione delle opzioni terapeutiche per l'amiloidosi AL. A conclusione della presentazione è prevista una sessione di domande e risposte in diretta.
Immix Biopharma (IMMX) ha anunciado un evento virtual con líderes de opinión clave (KOL) programado para el 3 de junio de 2025 a las 3:00 pm ET. En el evento se discutirán datos clínicos interinos del ensayo clínico de fase 1/2 NEXICART-2 sobre la terapia celular NXC-201 en pacientes con amiloidosis AL en recaída/refractaria, tras su presentación en la conferencia 2025 de la Sociedad Americana de Oncología Clínica (ASCO).
El evento contará con expertos destacados como la Dra. Heather Landau del Memorial Sloan-Kettering Cancer Center, el Dr. Shahzad Raza de la Cleveland Clinic y el Dr. Jeffrey Zonder del Karmanos Cancer Institute. Estos especialistas compartirán su experiencia clínica con NXC-201 y discutirán la evolución del tratamiento para la amiloidosis AL. Después de la presentación habrá una sesión de preguntas y respuestas en vivo.
Immix Biopharma (IMMX)는 2025년 6월 3일 오후 3시 ET에 예정된 가상 Key Opinion Leader(KOL) 행사를 발표했습니다. 이 행사에서는 2025년 미국임상종양학회(ASCO) 컨퍼런스에서 발표된 후 재발/불응성 AL 아밀로이드증 환자를 대상으로 한 세포 치료제 NXC-201의 NEXICART-2 1/2상 임상 시험의 중간 임상 데이터를 논의할 예정입니다.
행사에는 Memorial Sloan-Kettering Cancer Center의 Dr. Heather Landau, Cleveland Clinic의 Dr. Shahzad Raza, Karmanos Cancer Institute의 Dr. Jeffrey Zonder 등 저명한 전문가들이 참여합니다. 이 전문가들은 NXC-201에 대한 임상 경험을 공유하고 AL 아밀로이드증 치료 환경의 변화에 대해 논의할 것입니다. 발표 후에는 라이브 질의응답 세션이 진행됩니다.
Immix Biopharma (IMMX) a annoncé un événement virtuel avec des leaders d'opinion clés (KOL) prévu pour le 3 juin 2025 à 15h00 ET. Cet événement portera sur les données cliniques intermédiaires de l'essai clinique de phase 1/2 NEXICART-2 concernant leur thérapie cellulaire NXC-201 chez des patients atteints d'amylose AL réfractaire ou en rechute, suite à sa présentation lors de la conférence 2025 de l'American Society of Clinical Oncology (ASCO).
L'événement réunira des experts de renom tels que le Dr Heather Landau du Memorial Sloan-Kettering Cancer Center, le Dr Shahzad Raza de la Cleveland Clinic et le Dr Jeffrey Zonder du Karmanos Cancer Institute. Ces spécialistes partageront leur expérience clinique avec le NXC-201 et discuteront de l'évolution du paysage thérapeutique de l'amylose AL. Une session de questions-réponses en direct suivra la présentation.
Immix Biopharma (IMMX) hat eine virtuelle Key Opinion Leader (KOL) Veranstaltung angekündigt, die für den 3. Juni 2025 um 15:00 Uhr ET geplant ist. Bei der Veranstaltung werden vorläufige klinische Daten der Phase 1/2 NEXICART-2 Studie zur Zelltherapie NXC-201 bei Patienten mit rezidivierender/refraktärer AL-Amyloidose vorgestellt, nachdem diese bereits auf der 2025 American Society of Clinical Oncology (ASCO) Konferenz präsentiert wurden.
Die Veranstaltung wird von renommierten Experten wie Dr. Heather Landau vom Memorial Sloan-Kettering Cancer Center, Dr. Shahzad Raza von der Cleveland Clinic und Dr. Jeffrey Zonder vom Karmanos Cancer Institute begleitet. Diese Spezialisten werden ihre klinischen Erfahrungen mit NXC-201 teilen und die sich entwickelnde Behandlungssituation für AL-Amyloidose diskutieren. Im Anschluss an die Präsentation findet eine Live-Fragerunde statt.
- None.
- None.
– Virtual KOL Event Tuesday, June 3, 2025 3:00pm ET –
– Attend the event here: https://lifescievents.com/event/immix-asco –
LOS ANGELES, CA, May 21, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it will host a virtual Key Opinion Leader (KOL) event to discuss interim clinical data from the NEXICART-2 Phase 1/2 clinical trial of cell therapy NXC-201 in patients with relapsed/refractory AL Amyloidosis following its 2025 American Society of Clinical Oncology (ASCO) Oral Presentation in Chicago, IL.
The virtual KOL event will take place on Tuesday, June 3, 2025 at 3:00pm ET.
A live question and answer session will follow the discussion.
The event will feature Heather Landau, MD (Memorial Sloan-Kettering Cancer Center), Shahzad Raza, MD (Cleveland Clinic), and Jeffrey Zonder, MD (Karmanos Cancer Institute) who will discuss their clinical experience with NXC-201 cell therapy and the evolving treatment landscape for relapsed/refractory AL Amyloidosis.
Investors and other interested parties may join the live webcast through this weblink or visit the Immix website under Presentations & Events.
About Heather Landau, MD
Heather Landau, MD, is the Director of Amyloidosis Program and a Bone Marrow Transplant Specialist & Cellular Therapist at Memorial Sloan-Kettering Cancer Center in New York, with extensive experience designing clinical trials in hematology and oncology, novel treatment approaches for AL amyloidosis, and thought leadership.
Dr. Landau has authored more than 100 peer-reviewed publications. Dr. Landau received her medical degree from SUNY Upstate Medical University, completed her Internal Medicine residency at University of Colorado and her Hematology & Oncology fellowship at Memorial Sloan Kettering Cancer Center. Dr. Landau is board certified in Internal Medicine, Medical Oncology and Hematology.
About Shahzad Raza, MD
Shahzad Raza, MD is a hematologist/oncologist at Cleveland Clinic specializing in plasma cell dyscrasias, including AL Amyloidosis. Dr. Raza has authored numerous peer-reviewed publications over the last decade in academic medical practice. Dr. Raza completed his residency in internal medicine at the Brookdale Hospital Medical Center and his fellowship at the University of Missouri Hospitals & Clinics.
About Jeffrey Zonder, MD
Jeffrey Zonder, MD leads the Amyloidosis multi-disciplinary team at the Barbara Ann Karmanos Cancer Institute. He is Professor, Department of Oncology, Wayne State University School of Medicine, Detroit, MI. Dr Zonder is also the co-leader and a scientific member of the Molecular Therapeutics Program at the Barbara Ann Karmanos Cancer Institute. Dr. Zonder received his medical degree from Wayne State University, completed his residency at Strong Memorial Hospital of the Univ. of Rochester and his fellowship at Wayne State University.
About NEXICART-2
NEXICART-2 (NCT06097832) is an ongoing single-arm multi-site U.S. Phase 1/2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis. NEXICART-2 is expected to enroll 40 patients with preserved heart function (excluding patients with pre-existing heart failure) who have not been exposed to prior BCMA-targeted therapy. The primary endpoint of the Phase 1 portion is safety. The primary endpoint of the Phase 2 portion is efficacy.
About NXC-201
NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy with a “digital filter” that filters out non-specific activation. Initial data from ex-U.S. study NEXICART-1 has demonstrated high complete response rates in relapsed/refractory AL Amyloidosis. U.S. Phase 1/2 study NEXICART-2 is ongoing. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the FDA, and Orphan Drug Designation (ODD) by the US FDA and in the EU by the EMA.
About AL Amyloidosis
AL amyloidosis is caused by abnormal plasma cells in the bone marrow, which produce misfolded amyloid proteins that build-up in the heart, kidney, liver, and other organs. This build-up causes progressive and widespread organ damage, including heart and renal failure, leading to high mortality rates.
The U.S. observed prevalence of relapsed/refractory AL Amyloidosis is estimated to be growing at
The Amyloidosis market was
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201. NXC-201 is being evaluated in the U.S. study NEXICART-2 (NCT06097832) as well as the ex-U.S. study NEXICART-1 (NCT04720313). NXC-201 has demonstrated no neurotoxicity in AL Amyloidosis, supporting expansion into other serious diseases. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at www.immixbio.com and www.BeProactiveInAL.com.
Forward Looking Statements
This press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, the potential benefits of our product candidate CAR-T NXC-201 and the timing and results related clinical trials. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects”, “contemplates”, “anticipates”, “plans”, “intends”, “believes”, “estimates”, “potential”, and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the further data from the ongoing Phase 1/2 clinical trials for CAR-T NXC-201 will not be favorably consistent with the data readouts to date, (ii) the risk that the Company may not be able to continue the NEXICART-2 multi-site U.S. Phase 1/2 clinical trial; (iii) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (iv) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (v) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (vi) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for CAR-T NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (vii) those other risks disclosed in the section “Risk Factors” included in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2025 and other periodic reports subsequently filed with the Securities and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
Company Contact
irteam@immixbio.com
FAQ
When is Immix Biopharma's (IMMX) KOL event for NXC-201 ASCO data?
Who are the key opinion leaders presenting at IMMX's June 2025 event?
What clinical trial data will be discussed at Immix Biopharma's KOL event?
How can investors attend IMMX's June 2025 KOL event?
